Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients
Language English Country Greece Media print
Document type Journal Article
PubMed
29277808
DOI
10.21873/anticanres.12243
PII: 38/1/449
Knihovny.cz E-resources
- Keywords
- Renal cell carcinoma, cancer registry, pazopanib, response, survival,
- MeSH
- Databases, Factual MeSH
- Adult MeSH
- Indazoles MeSH
- Indoles therapeutic use MeSH
- Angiogenesis Inhibitors adverse effects therapeutic use MeSH
- Carcinoma, Renal Cell drug therapy pathology surgery MeSH
- Middle Aged MeSH
- Humans MeSH
- Kidney Neoplasms drug therapy pathology surgery MeSH
- Nephrectomy MeSH
- Disease-Free Survival MeSH
- Proto-Oncogene Proteins c-kit antagonists & inhibitors MeSH
- Pyrimidines adverse effects therapeutic use MeSH
- Pyrroles therapeutic use MeSH
- Receptors, Platelet-Derived Growth Factor antagonists & inhibitors MeSH
- Receptors, Vascular Endothelial Growth Factor antagonists & inhibitors MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Sulfonamides adverse effects therapeutic use MeSH
- Sunitinib MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Indazoles MeSH
- Indoles MeSH
- Angiogenesis Inhibitors MeSH
- pazopanib MeSH Browser
- Proto-Oncogene Proteins c-kit MeSH
- Pyrimidines MeSH
- Pyrroles MeSH
- Receptors, Platelet-Derived Growth Factor MeSH
- Receptors, Vascular Endothelial Growth Factor MeSH
- Sulfonamides MeSH
- Sunitinib MeSH
BACKGROUND: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. PATIENTS AND METHODS: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. RESULTS: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. CONCLUSION: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.
Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Oncology University Hospital in Hradec Králové Hradec Králové Czech Republic
Faculty of Medicine Masaryk University Brno Brno Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
References provided by Crossref.org
